title: Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report.
abstract: Omalizumab is approved for the treatment of chronic severe persistent asthma. As a trigger for anaphylaxis, the frequency of subcutaneous specific immunotherapy (SCIT) is high. We report the case of a 11-year-old boy with severe allergic asthma. During the initial phase of immunotherapy he experienced anaphylaxis and SCIT was discontinued. Because of uncontrolled asthma, despite the inhaled steroids and β-agonists were taken into consideration, omalizumab 300 mg once every 4 weeks was initiated. Currently, the maintenance dose has been reached and SCIT is continued without any side effects. The clinical implication of the above case report is that children with severe allergic asthma who are pre-treated with omalizumab might also benefit in the future from SIT as a causal treatment option.
authors.affiliation: Department of Pediatrics and Allergy, Medical University of Lodz, Poland. Head: Prof. Iwona Stelmach MD, PhD.
authors.forename: Iwona
authors.initials: I
authors.lastname: Stelmach
authors.affiliation: Department of Pediatrics and Allergy, Medical University of Lodz, Poland. Head: Prof. Iwona Stelmach MD, PhD.
authors.forename: Anna
authors.initials: A
authors.lastname: Sztafińska
authors.affiliation: Department of Pediatrics and Allergy, Medical University of Lodz, Poland. Head: Prof. Iwona Stelmach MD, PhD.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Woicka-Kolejwa
authors.affiliation: Department of Pediatrics and Allergy, Medical University of Lodz, Poland. Head: Prof. Iwona Stelmach MD, PhD.
authors.forename: Joanna
authors.initials: J
authors.lastname: Jerzyńska
keywords: anaphylaxis; asthma; immunotherapy; omalizumab; prophylaxis
references.citation: Postepy Dermatol Alergol. 2014 Feb;31(1):39-44
references.pmid: 24683397
references.citation: Postepy Dermatol Alergol. 2013 Aug;30(4):218-25
references.pmid: 24278078
references.citation: Pediatr Allergy Immunol. 2013 Aug;24(5):427-33
references.pmid: 23799935
references.citation: Postepy Dermatol Alergol. 2013 Jun;30(3):192-4
references.pmid: 24278073
references.citation: Postepy Dermatol Alergol. 2014 Feb;31(1):1-5
references.pmid: 24683390
references.citation: J Dermatol. 2012 Jun;39(6):552-4
references.pmid: 22390871
references.citation: Clin Exp Allergy. 2009 Feb;39(2):271-9
references.pmid: 19016798
references.citation: Ann Allergy Asthma Immunol. 2009 Mar;102(3):257-8
references.pmid: 19354075
references.citation: Postepy Dermatol Alergol. 2014 Feb;31(1):32-5
references.pmid: 24683395
references.citation: Allergol Immunopathol (Madr). 2013 Jul-Aug;41(4):255-60
references.pmid: 23063261